IBI 3002
Alternative Names: IBI-3002Latest Information Update: 15 Sep 2026
At a glance
- Originator Innovent Biologics
- Class Anti-inflammatories; Antiasthmatics; Bispecific antibodies; Skin disorder therapies
- Mechanism of Action Interleukin 4 receptor alpha subunit antagonists; Thymic stromal lymphopoietin inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Atopic dermatitis
- Phase I Asthma
Most Recent Events
- 20 May 2026 Adverse events and pharmacodynamic data from a phase I trial in Asthma presented at the 122nd International Conference of the American Thoracic Society (ATS 2026)
- 18 May 2026 Efficacy and adverse event data from a phase I trial in Asthma released by Innovent Biologics
- 11 May 2026 Innovent Biologics completes a Phase-I trial in Asthma in China (IV) (NCT06947408)